102 related articles for article (PubMed ID: 16772001)
1. Resistance to sulphadrug-based antifolate therapy in malaria: are we looking in the right place?
Platteeuw JJ
Trop Med Int Health; 2006 Jun; 11(6):804-8. PubMed ID: 16772001
[TBL] [Abstract][Full Text] [Related]
2. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum.
Wang P; Wang Q; Aspinall TV; Sims PF; Hyde JE
Mol Microbiol; 2004 Mar; 51(5):1425-38. PubMed ID: 14982635
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of de novo folate enzymes in Plasmodium falciparum.
Nzila A
Drug Discov Today; 2006 Oct; 11(19-20):939-44. PubMed ID: 16997145
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Tahar R; Basco LK
Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance of malaria parasites to antifolates.
Gregson A; Plowe CV
Pharmacol Rev; 2005 Mar; 57(1):117-45. PubMed ID: 15734729
[TBL] [Abstract][Full Text] [Related]
6. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection.
Nzila A
J Antimicrob Chemother; 2006 Jun; 57(6):1043-54. PubMed ID: 16617066
[TBL] [Abstract][Full Text] [Related]
7. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
[TBL] [Abstract][Full Text] [Related]
8. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
[TBL] [Abstract][Full Text] [Related]
9. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
Barnes KI; Little F; Mabuza A; Mngomezulu N; Govere J; Durrheim D; Roper C; Watkins B; White NJ
J Infect Dis; 2008 Jun; 197(11):1605-13. PubMed ID: 18471066
[TBL] [Abstract][Full Text] [Related]
10. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene.
Alifrangis M; Lusingu JP; Mmbando B; Dalgaard MB; Vestergaard LS; Ishengoma D; Khalil IF; Theander TG; Lemnge MM; Bygbjerg IC
Am J Trop Med Hyg; 2009 Apr; 80(4):523-7. PubMed ID: 19346369
[TBL] [Abstract][Full Text] [Related]
11. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
[TBL] [Abstract][Full Text] [Related]
12. Folate metabolism in malaria.
Ferone R
Bull World Health Organ; 1977; 55(2-3):291-8. PubMed ID: 338184
[TBL] [Abstract][Full Text] [Related]
13. Antifolates can have a role in the treatment of Plasmodium vivax.
Hawkins VN; Joshi H; Rungsihirunrat K; Na-Bangchang K; Sibley CH
Trends Parasitol; 2007 May; 23(5):213-22. PubMed ID: 17368986
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
Ndounga M; Tahar R; Basco LK; Casimiro PN; Malonga DA; Ntoumi F
Trop Med Int Health; 2007 Oct; 12(10):1164-71. PubMed ID: 17956498
[TBL] [Abstract][Full Text] [Related]
15. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance hampers our capacity to roll back malaria.
Olliaro P
Clin Infect Dis; 2005 Aug; 41 Suppl 4():S247-57. PubMed ID: 16032560
[TBL] [Abstract][Full Text] [Related]
17. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Bolaji OM; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Am J Trop Med Hyg; 2006 Jul; 75(1):155-61. PubMed ID: 16837724
[TBL] [Abstract][Full Text] [Related]
18. [Antimalarial drug resistance].
Le Bras J; Musset L; Clain J
Med Mal Infect; 2006 Aug; 36(8):401-5. PubMed ID: 16854546
[TBL] [Abstract][Full Text] [Related]
19. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates.
Henry M; Diallo I; Bordes J; Ka S; Pradines B; Diatta B; M'Baye PS; Sane M; Thiam M; Gueye PM; Wade B; Touze JE; Debonne JM; Rogier C; Fusai T
Am J Trop Med Hyg; 2006 Jul; 75(1):146-51. PubMed ID: 16837722
[TBL] [Abstract][Full Text] [Related]
20. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.
Babiker HA; Hastings IM; Swedberg G
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):581-93. PubMed ID: 19485798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
